Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate
Causes include viral gastroenteritis, foodborne illness, or bacterial infections
Food Funct 2016;7:184963.ArticlePubMed 13
Skipping Meals Because Youre Not Hungry Its common to forget to eat when youre taking GLP-1 medications, especially during the first few weeks of treatment
Cancer Cell Int (2010) 10:28
If you are considering comparable alternatives, the three-way comparison of semaglutide, tirzepatide, and retatrutide offers a useful overview of how these related compounds differ